Last updated: July 17, 2015

Thank you for your interest in Meda Pharmaceuticals Inc. Meda invites you to explore our websites and learn more about us and our products. As you do so, please know that Meda respects your privacy and is committed to protecting the personal information that you share with us. This Privacy Policy summarizes our standards for collecting, using, storing and sharing the personal information that we, or companies that work with us, obtain from our websites.

Meda Pharmaceuticals Inc. is the United States subsidiary of Meda AB, a global specialty pharmaceutical company based in Sweden. This Privacy Policy applies only to Meda Pharmaceuticals Inc., and to Meda owned websites, and the data collected within those websites, specifically identified as intended for use only by residents of the United States and its territories that link to this policy.

Meda’s Privacy Policy does not apply to third–party online resources, even if our website offers courtesy links to them. Meda does not control the content or the privacy practices of third–party resources. Read the Privacy Policy of any website or other online resource that you visit to ensure that you understand and agree with it. (That applies to our Privacy Policy too – we want you to read it carefully). If you have questions about our policy, or how Meda protects the privacy of your personal information, you may contact us a

Meda Pharmaceuticals, Inc. reserves the right to update or change this Privacy Policy.

The term "personal information" is used to describe information that can be readily used to identify a specific living person. Examples of personal information that could potentially be collected within a Meda website include an individual’s name, an individual’s street address or an individual’s email address. Information that relates to an individual, but could not be used to identify a specific individual, is not considered “personal information”. For example, the state of residence alone would not be considered personal information, but if this were to be combined with an individual’s street address, this would be considered “personal information” as it could be used to identify a specific individual.

De–identified information is information that has been stripped of features that would permit the identification of the underlying individual. When de–identified information about multiple people is put together, it is referred to as "aggregated" and de–identified information. Meda reserves the right to choose to aggregate personal information obtained from individuals through a variety of different channels. Any data aggregation of personal information will be done in a manner consistent with this Privacy Policy and any additional privacy notifications provided.

Meda collects personal information to improve your experience as a user of Meda’s websites. Collected personal information enables Meda to provide topics of interest that are more relevant to you as a user. In addition, information collected via Meda websites can provide mechanisms to assist with the improvement of Meda products and services as well as help better design features and better identify resources that users would like to see Meda offer.

Meda collects personal information online through websites and other sponsored resources. At times, we will work with other companies that collect personal information at our request. When Meda works with a third party company, the work is regulated by an agreement that, among other things, requires the third party company to properly protect the personal information it collects for us.

There are an assortment of tools that Meda may employ to collect personal information, including, but not limited to:

Direct Collection. This is collecting personal information from you by requesting that you complete an online form or participate in an interactive survey or display. Contact details, such as your name, street address, email address, telephone number, birth date, etc. are often collected directly. So is health status, so that Meda can provide you with information that is more likely to be relevant.

"Cookies". At times Meda, and at times advertisers on our websites, will employ the use of cookies. A "cookie" is a data file that a website may place on your computer’s hard drive. In general, cookies are used to simplify and improve your communication and interaction with a website. A website sponsor's ability to use a cookie to retrieve information from your computer can help customize the presentation of products and services, or help the website sponsor enhance their services to you. Some cookies are temporary and erased when you leave the Internet or shut down; others stay on your computer unless or until they are removed. If you do not wish to receive cookies from Meda websites, you can adjust your Web browser’s preferences on your computer. Please be aware that you can still visit our websites if you refuse cookies; but you may find that some of the features do not work, or do not work as well. Meda does not use cookies to retrieve information from your computer unless the information is related to our website or your interaction with our website.

Meda may use Google Analytics, a third party provider of analytics tools or a similar third party service to analyze information about visits to our website. For information about opting out of Google Analytics, please visit

Some Internet browsers offer what often is referred to as "do not track" mechanisms for browser users to automatically signal privacy preferences to websites that they visit. Internet browsers have only begun to include these features relatively recently. Our website(s) do not currently respond to do-not-track-signals. We may revisit the issue in the future. In the meantime, however, you can exercise other choices available, including limiting the placement of browser cookies on your device using your browser's cookie control features and other choices described in this Policy.

Web pixels. These are tiny graphics similar to cookies. Web pixels collect information that cannot be used to identify you personally such as the addresses of websites you view, the website that you viewed immediately prior to visiting our website, or the address of the website where the link used to reach our website was accessed. In addition, web pixels can be used to monitor whether email communications have been opened.

In general, Meda websites are not directed at children and most of the online services offered by Meda are designed for adults, age 18 or older.

Where available, you may update personal information by modifying information that was previously entered into either a Web form or data fields located within a Meda website. If you wish to access personal information collected by Meda, you may contact for purposes of ensuring accuracy or completeness of personal information. Please be aware that you may not always be able to access the information that has been collected. For instance, your ability to access and correct personal information will be limited where we believe it would interfere with our ability to fulfill legal or ethical obligations or to address legal claims. Access and correction of personal information will not be allowed if it would result in disclosure of a third party's personal information, or lead to a breach of contract or disclosure of trade secrets or other protected business information.

Meda strives to protect personal information as it is transmitted from your computer to our websites. Due to the open nature of the Internet, Meda cannot guarantee that our interactions with you, or your interactions with Meda, will be free from unauthorized access by third parties. Meda protects our servers and data with a firewall and endeavors to protect personal information within our possession, custody, or control from unauthorized access, disclosure, alteration or destruction. Employees and business partners with access to your personal information must have a business–related "need to know" in order to perform their job functions for Meda. However, Meda also depends upon you to help secure information by protecting your own copies of passwords and related access codes for our websites.

Personal information is accessible to Meda, including its subsidiaries, divisions and groups worldwide, and to individuals and organizations that use personal information solely for, and at the direction of, Meda. Uses and disclosures of personal information by external individuals and organizations acting on Meda's behalf are governed by agreements that require personal information to be protected appropriately. Personal information about you only will be used and disclosed by Meda and individuals and organizations working on its behalf, in a manner consistent with this Privacy Policy, other applicable privacy notices, and as explicitly permitted or required by applicable laws, rules and regulations.

In general, Meda does not sell or barter your personal information to third parties. However, if Meda decides to reorganize or divest its business through sale, merger or acquisition, it is possible that personal information will be shared with actual or prospective buyers. If that happens, Meda will obtain a written agreement that personal information will be properly protected. Except where explicitly permitted, required by law, or provided in this Privacy Policy, personal information will not otherwise be shared without your consent.

You will have some choices about whether and/or when to share personal information with Meda. In cases where you are affirmatively requested to provide information, such as to complete a form, a survey, or application on a Meda website, you may decline to do so. Please understand, however, that in some cases certain information is required to complete an application, form, or survey, and if you decline to provide the information requested, you may not be able to use certain functionalities of our websites.

In addition, you may be given additional choices in the context of particular preferences tools or functions that are made available through Meda’s websites or opportunities to opt-out of future email or other communications using the opt-out choices offered within those communications.

More Important Safety Information

MUSE is contraindicated in men with any of the following:

  • Known hypersensitivity to alprostadil
  • Abnormal penile anatomy: MUSE is contraindicated in patients with urethral stricture, balanitis (inflammation/infection of the glans of the penis), severe hypospadias and curvature, and in patients with acute or chronic urethritis
  • Sickle cell anemia or trait, thrombocythemia, polycythemia, multiple myeloma: MUSE is contraindicated in patients who are prone to venous thrombosis or who have a hyperviscosity syndrome and are therefore at increased risk of priapism (rigid erection lasting 6 or more hours)
  • MUSE should not be used in men for whom sexual activity is inadvisable
  • MUSE should not be used for sexual intercourse with a pregnant woman unless the couple uses a condom barrier

Because of the potential for symptomatic hypotension and syncope, which occurred in 3% and 0.4%, respectively, of patients during in-clinic dosing, MUSE titration should be carried out under medical supervision. During post-marketing surveillance syncope occurring within one hour of administration has been reported. Patients should be cautioned to avoid activities, such as driving or hazardous tasks, where injury could result if hypotension or syncope were to occur after MUSE administration.

A complete medical history and physical examination should be undertaken to exclude reversible causes of erectile dysfunction prior to the initiation of MUSE therapy. In addition, underlying disorders that might preclude the use of MUSE should be sought.

Cardiovascular effects: During in-clinic dosing, patients should be monitored for symptoms of hypotension, and the lowest effective dose of MUSE should be prescribed.

Hematologic effects: Patients administering MUSE improperly may be at risk of urethral abrasion resulting in minor bleeding or spotting. Patients on anticoagulant therapy or with bleeding disorders may be at higher risk of bleeding. Patients on anticoagulant therapy have been safely treated with MUSE; however, the risk/benefit ratio in these patients should be considered prior to prescribing MUSE.

Resumption of sexual activity: Sexual intercourse is considered a vigorous physical activity, and it increases heart rate as well as cardiac work. Physicians may want to examine the cardiac fitness of patients prior to treating erectile dysfunction.

Priapism and prolonged erection: In clinical trials of MUSE, priapism (rigid erection lasting ≥ 6 hours) and prolonged erection (rigid erection lasting 4 hours and < 6 hours) were reported infrequently (< 0.1% and 0.3% of patients, respectively). Nevertheless, these events are a potential risk of pharmacologic therapy and can cause penile injury. Physicians should lower the dose or consider discontinuing MUSE treatment in any patient who develops priapism or prolonged erection.

Drug-Drug Interactions: Because there are low or undetectable (< 2 picograms/mL) amounts of alprostadil found in the peripheral venous circulation following MUSE administration, systemic drug-drug interactions with MUSE are unlikely. Although formal studies have not been conducted, the concomitant use of MUSE and anti-hypertensive medications may increase the risk of hypotension. It is therefore advised that caution be used in the administration of MUSE to individuals on anti-hypertensive medications. In addition, the presence of medications in the circulation that attenuate erectile function may influence the response to MUSE.

Drug-Device Interactions: Use of MUSE in patients with penile implants has not been studied.

Sexual Preference: There is no experience in homosexual men and no experience with other than vaginal intercourse.

In two double-blind, parallel, placebo-controlled trials, 1511 patients received MUSE at least 1 time in the clinic. The most frequently reported (≥ 2%) drug-related side effects during in-clinic titration included pain in the penis (36%), urethra (13%), or testes (5%), dizziness (4%), urethral bleeding/spotting and other minor abrasions to the urethra (3%), hypotension (3%), and syncope (0.4%).

996 patients (66% of those who began titration) were studied during the home treatment portion of the two studies. The most frequently reported (≥ 2%) adverse events with MUSE vs placebo, respectively, were penile pain (32% vs 3%), urethral burning (12% vs 4%), minor urethral bleeding/spotting (5% vs 1%), testicular pain (5% vs 1%), flu symptoms (4% vs 2%), headache (3% vs 2%), pain (3% vs 1%), accidental injury (3% vs 2%), respiratory infection (3% vs 2%), dizziness (2% vs < 1%), back pain (2% vs 1%), pelvic pain (2% vs < 1%) and rhinitis (2% vs < 1%).

The most common drug-related adverse event reported by female partners during placebo-controlled clinical studies was vaginal burning/itching, reported by 5.8% of partners of patients on active vs. 0.8% of partners of patients on placebo. It is unknown whether this adverse event experienced by female partners was a result of the medication or a result of resuming sexual intercourse, which occurred much more frequently in partners of patients on active medication.


MUSE is indicated for the treatment of erectile dysfunction. Studies that established benefit demonstrated improvements in success rates for sexual intercourse compared with similarly administered placebo.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 855-543-3784.

For additional information, please see the Full Prescribing Information.